Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease
Authors:
- Gorka LarrinagaGLGorka Larrinaga
- Jon Danel Solano-IturriJSJon Danel Solano-Iturri
- Inés Arrieta-AguirreIAInés Arrieta-Aguirre
- Asier ValdiviaAVAsier Valdivia
- David LecumberriDLDavid Lecumberri
- Ane Miren IturreguiAIAne Miren Iturregui
- Charles H. LawrieCLCharles H. Lawrie
- María ArmestoMAMaría Armesto
- Juan F. DoradoJDJuan F. Dorado
- Caroline E. Nunes-XavierCNCaroline E. Nunes-Xavier
- Rafael PulidoRafael Pulido
- José I. LópezJosé I. López
Open Access
- 7 March 2025
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 387
Abstract
Despite advances in the management of advanced clear cell renal cell carcinoma (ccRCC), robust biomarkers for prognosis and therapeutic response prediction remain elusive. Dysregulation of the intrarenal renin–angiotensin system (RAS) has been implicated in renal carcinogenesis but little explored, particularly regarding biomarker discovery and therapeutic innovation. Consequently, this study investigates the immunohistochemical expression and clinical relevance of the Mas-related G-protein-coupled receptor D (MrgD) in patients with ccRCC who developed metastatic disease (mccRCC). A cohort of 132 patients treated between 2008 and 2018 with nephrectomy and tyrosine kinase inhibitor (TKI)-based sequential therapy was analyzed. Treatment response was assessed using both the MASS and RECIST scoring systems. High MrgD expression in primary tumors was significantly associated with larger size, advanced stage, higher histological grade, and worse overall survival. Among 81 patients with metachronous metastases, high MrgD expression independently predicted shorter disease-free survival. High MrgD staining intensity correlated with poorer TKI responses in first-line therapy but improved outcomes with second-line mTORC1 inhibitors. These findings suggest that MrgD may be a useful biomarker of RAS linked to tumor aggressiveness in ccRCC. MrgD holds potential for identifying high-risk patients and guiding treatment selection in advanced disease. Further research is needed to unlock its clinical potential.Keywords
Funding Information
- Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (KK-202400003, IT1524-22, CP20/00008, PI22/00386)
- Instituto de Salud Carlos III (KK-202400003, IT1524-22, CP20/00008, PI22/00386)
- European Union (KK-202400003, IT1524-22, CP20/00008, PI22/00386)
This publication has 51 references indexed in Scilit:
- Kidney cancer: From tumor biology to innovative therapeuticsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell CarcinomaClinical Genitourinary Cancer, 2024
- The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysisClinical Genitourinary Cancer, 2024
- Alamandine, a protective component of the renin-angiotensin system, reduces cellular proliferation and interleukin-6 secretion in human macrophages through MasR–MrgDR heteromerizationBiochemical Pharmacology, 2024
- Diverse biological functions of the renin‐angiotensin systemMedicinal Research Reviews, 2023
- Role of the Renin–Angiotensin System Components in Renal Cell Carcinoma: A Literature ReviewCurrent Urology Reports, 2023
- Phosphoproteomic studies of alamandine signaling in CHO‐MrgD and human pancreatic carcinoma cells: An antiproliferative effect is unveiledProteomics, 2022
- Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsClinical Genitourinary Cancer, 2022
- Improved renal cancer prognosis among users of drugs targeting renin-angiotensin systemCancer Causes & Control, 2021
- Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathwayBiochemical and Biophysical Research Communications, 2015